Scholarlink

Objective <p>This study aimed to assess clinical benefits of semaglutide for East Asian non-diabetic obese patients with ACS who have undergone percutaneous coronary intervention (PCI) .</p> Method <p>This was a multicenter retrospective cohort study. A total of 344 non-diabetic obese patients with ACS who underwent PCI at three hospitals from May 2020 to December 2024 were enrolled (semaglutide group:112 patients, control group: 232 patients). Propensity score matching (PSM) was performed to balance the baseline data between the two groups. The primary endpoint was 6-month major adverse cardiovascular events (MACE), and secondary endpoints included dynamic changes in cardiac troponin I (cTnI) and alterations in metabolic and left ventricular ejection fraction (LVEF) at 6-month follow-up.</p> Results <p>After PSM, compared with the control group, the semaglutide group had lower rates of the 6-month MACE (11.6% vs. 23.2%, <i>p</i> = 0.034) and unplanned revascularization (4.7% vs. 13.4%, <i>p</i> = 0.033), and and showed faster improvement in cTnI levels. Both groups showed improvements in blood lipid profiles and LVEF post-PCI. Additionally, the semaglutide group achieved further reductions in fasting blood glucose (FBG) (5.74 ± 0.60mmol/L vs. 5.25 ± 0.43mmol/L, <i>p</i> &lt; 0.0001), glycated hemoglobin (HbA1c) (5.43 ± 0.59% vs. 5.18 ± 0.50%, <i>p</i> = 0.016) and body mass index (BMI) (30.94 ± 1.69&#xa0;kg/m²vs. 28.45 ± 2.82&#xa0;kg/m², <i>p</i> &lt; 0.0001). Particularly, the magnitudes of improvements in BMI (2.49 ± 3.27&#xa0;kg/m²vs. 0.78 ± 2.76&#xa0;kg/m², <i>p</i> = 0.002), FBG (0.49 ± 0.75mmol/L vs. 0.03 ± 0.83mmol/L, <i>p</i> &lt; 0.0001), LDL-C (1.78 ± 1.22mmol/L vs. 0.83 ± 0.94mmol/L, <i>p</i> &lt; 0.0001), TG (0.98 ± 1.02mmol/L vs. 0.63 ± 0.70mmol/L, <i>p</i> = 0.003) and LVEF (5.73 ± 8.07% vs. 2.66 ± 8.09%, <i>p</i> = 0.005) in the semaglutide group were significantly superior to those in the control group.</p> Conclusions <p>Semaglutide treatment was associated with a lower 6-month MACE and favorable changes in metabolic and cardiac function in non-diabetic obese ACS patients post-PCI. These observational findings provide real-world evidence for further study.</p> Clinical trial registration <p>This was a retrospective study, so clinical trial registration was not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Chao-lun Jin,
  • Lu Huang,
  • Ying-ying Wei,
  • Yun-shu Xu,
  • Bo Zhang,
  • Jing Wu,
  • Ling-long Fan

摘要

Objective

This study aimed to assess clinical benefits of semaglutide for East Asian non-diabetic obese patients with ACS who have undergone percutaneous coronary intervention (PCI) .

Method

This was a multicenter retrospective cohort study. A total of 344 non-diabetic obese patients with ACS who underwent PCI at three hospitals from May 2020 to December 2024 were enrolled (semaglutide group:112 patients, control group: 232 patients). Propensity score matching (PSM) was performed to balance the baseline data between the two groups. The primary endpoint was 6-month major adverse cardiovascular events (MACE), and secondary endpoints included dynamic changes in cardiac troponin I (cTnI) and alterations in metabolic and left ventricular ejection fraction (LVEF) at 6-month follow-up.

Results

After PSM, compared with the control group, the semaglutide group had lower rates of the 6-month MACE (11.6% vs. 23.2%, p = 0.034) and unplanned revascularization (4.7% vs. 13.4%, p = 0.033), and and showed faster improvement in cTnI levels. Both groups showed improvements in blood lipid profiles and LVEF post-PCI. Additionally, the semaglutide group achieved further reductions in fasting blood glucose (FBG) (5.74 ± 0.60mmol/L vs. 5.25 ± 0.43mmol/L, p < 0.0001), glycated hemoglobin (HbA1c) (5.43 ± 0.59% vs. 5.18 ± 0.50%, p = 0.016) and body mass index (BMI) (30.94 ± 1.69 kg/m²vs. 28.45 ± 2.82 kg/m², p < 0.0001). Particularly, the magnitudes of improvements in BMI (2.49 ± 3.27 kg/m²vs. 0.78 ± 2.76 kg/m², p = 0.002), FBG (0.49 ± 0.75mmol/L vs. 0.03 ± 0.83mmol/L, p < 0.0001), LDL-C (1.78 ± 1.22mmol/L vs. 0.83 ± 0.94mmol/L, p < 0.0001), TG (0.98 ± 1.02mmol/L vs. 0.63 ± 0.70mmol/L, p = 0.003) and LVEF (5.73 ± 8.07% vs. 2.66 ± 8.09%, p = 0.005) in the semaglutide group were significantly superior to those in the control group.

Conclusions

Semaglutide treatment was associated with a lower 6-month MACE and favorable changes in metabolic and cardiac function in non-diabetic obese ACS patients post-PCI. These observational findings provide real-world evidence for further study.

Clinical trial registration

This was a retrospective study, so clinical trial registration was not applicable.